drugset / Trial / NCT02748837
A Study of ERY974 in Patient With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Timeline
- Start
- 2016-08
- Primary completion
- 2019-08
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERY974 | Unknown | — | Intravenous |